{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:56:48Z","timestamp":1761872208479,"version":"build-2065373602"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.clml.2022.12.011","type":"journal-article","created":{"date-parts":[[2022,12,25]],"date-time":"2022-12-25T17:12:16Z","timestamp":1671988336000},"page":"159-167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["SOHO State of the Art Updates and Next Questions | Optimal Timing of Blinatumomab for the Treatment of B-Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"23","author":[{"given":"Ashley","family":"Pinchinat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumit","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacy L.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4096-6603","authenticated-orcid":false,"given":"Rachel E.","family":"Rau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.12.011_bib0001","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.12.011_bib0002","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41571-018-0087-y","article-title":"Eliminating MRD \u2014 FDA approval of blinatumomab for B-ALL in complete remission","volume":"15","author":"Hilal","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2022.12.011_bib0003","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.170.8.4397","article-title":"T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-\/CD3- bispecific single-chain antibody construct","volume":"170","author":"Dreier","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.clml.2022.12.011_bib0004","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ijc.10557","article-title":"Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody","volume":"100","author":"Dreier","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2022.12.011_bib0005","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.20908","article-title":"Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct","volume":"115","author":"Hoffmann","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2022.12.011_bib0006","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell\u2013engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.011_bib0007","doi-asserted-by":"crossref","unstructured":"Mocquot P, Mossazadeh Y, Lapierre L, Pineau F, Despas F. The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials. 2022 (n\/a).","DOI":"10.1111\/jcpt.13741"},{"key":"10.1016\/j.clml.2022.12.011_bib0008","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.011_bib0009","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/bcj.2014.64","article-title":"Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia","volume":"4","author":"Zugmaier","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.12.011_bib0010","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science (New York, NY)."},{"key":"10.1016\/j.clml.2022.12.011_bib0011","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.12.011_bib0012","doi-asserted-by":"crossref","unstructured":"Topp MS, G\u00f6kbuget N, Zugmaier G, et\u00a0al. Phase II trial of the anti-CD19 Bispecific T cell\u2013engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. 2014;32:4134-4140.","DOI":"10.1200\/JCO.2014.56.3247"},{"key":"10.1016\/j.clml.2022.12.011_bib0013","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.12.011_bib0014","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.12.011_bib0015","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1080\/10428194.2019.1576872","article-title":"Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia","volume":"60","author":"Dombret","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.12.011_bib0016","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.3324\/haematol.2021.280078","article-title":"High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL","volume":"107","author":"Cabannes-Hamy","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.12.011_bib0017","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood-2017-09-804658","article-title":"Health-related quality of life in adults with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab","volume":"131","author":"Topp","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.011_bib0018","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.011_bib0019","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1080\/10428194.2020.1780583","article-title":"Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia","volume":"61","author":"G\u00f6kbuget","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.12.011_bib0020","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1182\/bloodadvances.2019000457","article-title":"Molecular response with blinatumomab in relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"3","author":"G\u00f6kbuget","year":"2019","journal-title":"Blood advances"},{"key":"10.1016\/j.clml.2022.12.011_bib0021","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2147\/PROM.S149420","article-title":"Impact of blinatumomab on patient outcomes in relapsed\/refractory acute lymphoblastic leukemia: evidence to date","volume":"9","author":"Hathaway","year":"2018","journal-title":"Patient Relate Outcome Measures"},{"key":"10.1016\/j.clml.2022.12.011_bib0022","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.12.011_bib0023","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1038\/s41375-020-0770-8","article-title":"Blinatumomab versus historical standard therapy in pediatric patients with relapsed\/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia","volume":"34","author":"Locatelli","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.12.011_bib0024","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1182\/blood.2019004043","article-title":"How I treat relapsed acute lymphoblastic leukemia in the pediatric population","volume":"136","author":"Hunger","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.011_bib0025","volume":"134","author":"Brown","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.011_bib0026","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2022.12.011_bib0027","volume":"138:","author":"Brown","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.011_bib0028","doi-asserted-by":"crossref","first-page":"e29715","DOI":"10.1002\/pbc.29715","article-title":"Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia","volume":"69","author":"Locatelli","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2022.12.011_bib0029","doi-asserted-by":"crossref","first-page":"e878","DOI":"10.1016\/S2352-3026(22)00285-X","article-title":"Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial","volume":"9","author":"Jabbour","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.12.011_bib0030","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2022-171751","volume":"140:","author":"Litzow","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.011_bib0031","first-page":"1","article-title":"Cutting to the front of the line: immunotherapy for childhood acute lymphoblastic leukemia","volume":"40","author":"McNeer","year":"2020","journal-title":"Am Society Clin Oncol Educ Book Am Soc Clin Oncol Annual Meet"},{"key":"10.1016\/j.clml.2022.12.011_bib0032","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s43046-022-00126-3","article-title":"Jude total therapy studies from I to XVII for childhood acute lymphoblastic leukemia: a brief review","volume":"34","author":"Omar","year":"2022","journal-title":"J Egypt Natl Canc Inst"},{"key":"10.1016\/j.clml.2022.12.011_bib0033","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.19.00261","article-title":"Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the interfant-06 protocol: results from an international phase III randomized study","volume":"37","author":"Pieters","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.12.011_bib0034","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood.2019004008","article-title":"Blinatumomab for infant acute lymphoblastic leukemia","volume":"135","author":"Clesham","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.12.011_bib0035","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-144843","article-title":"A phase 2 study to test the feasibility, safety and efficacy of the addition of blinatumomab to the interfant06 backbone in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia. a collaborative study of the interfant network","volume":"138","author":"Van Der Sluis","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.011_bib0036","doi-asserted-by":"crossref","unstructured":"Martinelli G, Boissel N, Chevallier P, et\u00a0al. Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome\u2013positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. 2017;35:1795-1802.","DOI":"10.1200\/JCO.2016.69.3531"},{"key":"10.1016\/j.clml.2022.12.011_bib0037","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2020.12.022","article-title":"Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome\u2013positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study","volume":"146","author":"Martinelli","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2022.12.011_bib0038","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib\u2013blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.12.011_bib0039","doi-asserted-by":"crossref","unstructured":"Chiaretti S, Bassan R, Vitale A, et\u00a0al. P353: forty months update of the Gimema lal2116 (d-alba) protocol and ancillary lal2217 study for newly diagnosed adult Ph+ all. 2022;6:253-254.","DOI":"10.1097\/01.HS9.0000844300.04335.af"},{"key":"10.1016\/j.clml.2022.12.011_bib0040","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jamaoncol.2022.2398","article-title":"Treatment of adults with philadelphia chromosome-positive acute lymphoblastic leukemia-from intensive chemotherapy combinations to chemotherapy-free regimens: a review","volume":"8","author":"Jabbour","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.clml.2022.12.011_bib0041","doi-asserted-by":"crossref","first-page":"S204","DOI":"10.1016\/S2152-2650(22)01203-4","article-title":"ALL-424 updated results from the phase II study of blinatumomab in combination with ponatinib in philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"22","author":"Haddad","year":"2022","journal-title":"Clin Lymph Myeloma Leukemia"},{"key":"10.1016\/j.clml.2022.12.011_bib0042","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1002\/cncr.23819","article-title":"Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia","volume":"113","author":"O'Brien","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.12.011_bib0043","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1470-2045(18)30011-1","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study","volume":"19","author":"Kantarjian","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.12.011_bib0044","doi-asserted-by":"crossref","unstructured":"Macaron W, Kantarjian HM, Short NJ, et\u00a0al. Updated results from a phase II study of mini-hyper-CVD (mini-HCVD) plus inotuzumab ozogamicin (INO), with or without blinatumomab (Blina), in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL). 2022;40(16_suppl):7011-7011.","DOI":"10.1200\/JCO.2022.40.16_suppl.7011"},{"key":"10.1016\/j.clml.2022.12.011_bib0045","doi-asserted-by":"crossref","unstructured":"Advani AS, Moseley A, O'Dwyer KM, et\u00a0al. SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome\u2013negative B-cell acute lymphoblastic leukemia. 2022;40:1574-1582.","DOI":"10.1200\/JCO.21.01766"},{"key":"10.1016\/j.clml.2022.12.011_bib0046","doi-asserted-by":"crossref","DOI":"10.1182\/hem.V19.3.2022316","article-title":"A chemotherapy-free regimen for older adults and relapsed or refractory B-ALL","volume":"19","author":"O\u2019Dwyer","year":"2022","journal-title":"Hematol"},{"key":"10.1016\/j.clml.2022.12.011_bib0047","doi-asserted-by":"crossref","first-page":"e26824","DOI":"10.1002\/pbc.26824","article-title":"Blinatumomab activity in a patient with Down syndrome B-precursor acute lymphoblastic leukemia","volume":"65","author":"Wadhwa","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2022.12.011_bib0048","doi-asserted-by":"crossref","first-page":"e29044","DOI":"10.1002\/pbc.29044","article-title":"Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed\/refractory b-precursor acute lymphoblastic leukaemia: Case reports and literature review","volume":"68","author":"Sora","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.12.011_bib0049","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-148967","article-title":"Blinatumomab associated seizure risk in patients with down syndrome and B-lymphoblastic leukemia: an interim report from Children's Oncology Group (COG) study AALL1731","volume":"138","author":"Li","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.011_bib0050","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.12.011_bib0051","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.12.011_bib0052","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.12.011_bib0053","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","author":"Laetsch","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.12.011_bib0054","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.12.011_bib0055","doi-asserted-by":"crossref","unstructured":"Maude SL, Teachey DT, Rheingold SR, et\u00a0al. Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed\/refractory ALL. 2016;34(15_suppl):3011-3011.","DOI":"10.1200\/JCO.2016.34.15_suppl.3011"},{"key":"10.1016\/j.clml.2022.12.011_bib0056","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","volume":"35","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.12.011_bib0057","article-title":"Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells","author":"Lamble","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.12.011_bib0058","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.929122","article-title":"The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis","volume":"10","author":"Marrapodi","year":"2022","journal-title":"Front pediatr"},{"key":"10.1016\/j.clml.2022.12.011_bib0059","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/bjh.18314","article-title":"Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease","volume":"198","author":"Yeoh","year":"2022","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.12.011_bib0060","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1182\/blood-2022-157117","article-title":"Safety and pharmacokinetics of subcutaneous blinatumomab (SC blinatumomab) for the treatment of adults with relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R\/R B-ALL); results from a phase 1b study","volume":"140","author":"Mart\u00ednez S\u00e1nchez","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.011_bib0061","doi-asserted-by":"crossref","first-page":"93309","DOI":"10.18632\/oncotarget.22071","article-title":"Blinatumomab in Ph+ B-ALL: present and perspectives","volume":"8","author":"Papayannidis","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2022.12.011_bib0062","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.12.011_bib0063","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502201775X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502201775X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:58Z","timestamp":1761871318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502201775X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S215226502201775X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.12.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Optimal Timing of Blinatumomab for the Treatment of B-Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}